Skip to main content
Terug
CLPBY logo

Coloplast A/S

Datakwaliteit: 100%
Oversold
CLPBY
OTC Healthcare Medical - Instruments & Supplies
€ 6,58
▼ € 0,01 (-0,08%)
Marktkapitalisatie: 14,82B
Ook genoteerd als CLPBF OTC
Dagbereik
€ 6,53 € 6,72
52-Weeksbereik
€ 6,53 € 11,44
Volume
96.729
50D / 200D Gem.
€ 7,87 / € 8,90
Vorige Slotkoers
€ 6,59

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 4,3 0,4
P/B 0,9 2,9
ROE % 20,1 3,8
Net Margin % 13,1 3,9
Rev Growth 5Y % 7,8 10,0
D/E 1,4 0,2

Belangrijkste Punten

Revenue grew 7,82% annually over 5 years — modest growth
Earnings declined -32,21% over the past year
ROE of 20,09% indicates high profitability
Generating 5,03B in free cash flow
P/E of 4,33 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 10,69%

Groei

Revenue Growth (5Y)
7,82%
Revenue (1Y)-2,87%
Earnings (1Y)-32,21%
FCF Growth (3Y)29,80%

Kwaliteit

Return on Equity
20,09%
ROIC13,79%
Net Margin13,05%
Op. Margin27,19%

Veiligheid

Debt / Equity
1,40
Current Ratio1,61
Interest Coverage9,19

Waardering

P/E Ratio
4,33
P/B Ratio0,92
EV/EBITDA5,12
Dividend Yield0,04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -2,87% Revenue Growth (3Y) 3,52%
Earnings Growth (1Y) -32,21% Earnings Growth (3Y) -15,38%
Revenue Growth (5Y) 7,82% Earnings Growth (5Y) -8,21%
Profitability
Revenue (TTM) 26,25B Net Income (TTM) 3,43B
ROE 20,09% ROA 7,07%
Gross Margin 65,06% Operating Margin 27,19%
Net Margin 13,05% Free Cash Flow (TTM) 5,03B
ROIC 13,79% FCF Growth (3Y) 29,80%
Safety
Debt / Equity 1,40 Current Ratio 1,61
Interest Coverage 9,19 Dividend Yield 0,04%
Valuation
P/E Ratio 4,33 P/B Ratio 0,92
P/S Ratio 0,56 PEG Ratio -1,10
EV/EBITDA 5,12 Dividend Yield 0,04%
Market Cap 14,82B Enterprise Value 36,55B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 26,25B 27,03B 24,50B 22,58B 19,43B
Net Income 3,43B 5,05B 4,78B 4,71B 4,83B
EPS (Diluted) 1,52 2,25 2,22 2,21 2,26
Gross Profit 17,08B 18,27B 16,33B 15,53B 13,31B
Operating Income 7,14B 7,32B 6,77B 6,44B 6,36B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 48,46B 48,07B 48,16B 34,96B 15,84B
Total Liabilities 32,31B 30,13B 30,86B 26,66B 7,67B
Shareholders' Equity 16,15B 17,94B 17,30B 8,29B 8,17B
Total Debt 22,68B 22,63B 19,57B 18,71B 2,79B
Cash & Equivalents 948,88M 788,00M 911,00M 414,00M 448,00M
Current Assets 10,47B 10,44B 9,94B 8,77B 6,99B
Current Liabilities 6,52B 10,20B 16,31B 7,34B 6,31B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Contrarian Investing (David Dreman)
#216 of 658
42

Recente Activiteit

Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026